Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 21;11(3):399.
doi: 10.3390/cancers11030399.

Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions

Angelica Petrillo  1 , Luca Pompella  2 , Giuseppe Tirino  3 , Annalisa Pappalardo  4 , Maria Maddalena Laterza  5 , Marianna Caterino  6 , Michele Orditura  7 , Fortunato Ciardiello  8 , Eva Lieto  9 , Gennaro Galizia  10 , Carlo Castoro  11 , Ferdinando De Vita  12
Affiliations
Review

Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions

Angelica Petrillo et al. Cancers (Basel). .

Abstract

Gastric cancer (GC) is the fifth-most common cancer worldwide and an important cause of cancer-related-death. The growing knowledge of its molecular pathogenesis has shown that GC is not a single entity, but a constellation of different diseases, each with its own molecular and clinical characteristics. Currently, surgery represents the only curative approach for localized GC, but only 20% of patients (pts) showed resectable disease at diagnosis and, even in case of curative resection, the prognosis remains poor due to the high rate of disease relapse. In this context, multimodal perioperative approaches were developed in western and eastern countries in order to decrease relapse rates and improve survival. However, there is little consensus about the optimal treatment for non-metastatic GC. In this review, we summarize the current status and future developments of perioperative chemotherapy in resectable GC, attempting to find clear answers to the real problems in clinical practice.

Keywords: gastric cancer; neoadjuvant chemotherapy; perioperative treatment.

PubMed Disclaimer

Conflict of interest statement

Angelica Petrillo: grant from Lilly; Michele Orditura: Honoraria from Italfarmaco, EISAI, epionpharma, Roche; Fortunato Ciardiello: Advisory Boards: Roche, Amgen, Merck, Pfizer, Sanofi, Bayer, Servier, BMS, Celgene, Lilly; Institutional Research Grants: Bayer, Roche, Merck, Amgen, AstraZeneca, Takeda; Ferdinando De Vita: Advisory Boards: Roche, Amgen, Celgene, Lilly. The authors have no conflicts of interest to declare. The funders had no role in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Rates of patients that received pre and postoperative treatment in the principle Phase III of MAGIC [7], FFCD-ACCORD [8], and FLOT-4 [10,11] clinical trials.
See this image and copyright information in PMC

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Coebergh J.W., Comber H., Forman D., Bray F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur. J. Cancer. 2013;49:1374–1403. doi: 10.1016/j.ejca.2012.12.027. - DOI - PubMed
    1. Tirino G., Pompella L., Petrillo A., Laterza M.M., Pappalardo A., Caterino M., Orditura M., Ciardiello F., Galizia G., De Vita F. What’s New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives. Int. J. Mol. Sci. 2018;7:19. doi: 10.3390/ijms19092659. - DOI - PMC - PubMed
    1. Lauren P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol. Microbiol. Scand. 1965;64:31–49. doi: 10.1111/apm.1965.64.1.31. - DOI - PubMed
    1. Cancer Genome Atlas Research Network Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–209. doi: 10.1038/nature13480. - DOI - PMC - PubMed

LinkOut - more resources